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been identified in some studies as an independent predic-
tor of decreased stent patency after iliac angioplasty and
stenting.3,5,6,8 We recently reported the outcome of
endovascular treatment of iliac occlusive disease in women
as well as predictors of poor outcome.9 In this previous
study, men were not included. The primary patency rate
for women who had EIA stents was only 43% at 36
months. The presence of an EIA lesion and the use of hor-
mone replacement therapy (HRT) were identified as inde-
pendent predictors of failed primary stent patency. In the
current study, a more recent time frame was chosen, which
better represents our current approach, with most iliac
angioplasty and stenting procedures performed in the
operating room by vascular surgeons.
Although EIA angioplasty and stenting procedures are
generally associated with decreased primary patency, multi-
variate analyses have provided conflicting results when
patients with different grades of iliac occlusive disease are
included.5,8,10,11 Lee et al,12 for instance, have reported
similar patency rates for EIA and CIA stents, although only
men were included in their study. In other recent reports,
investigators have examined the endovascular treatment of
multisegment iliac occlusive disease and have shown more
Iliac artery angioplasty and stenting are established
treatments of aortoiliac occlusive disease, generally applied
to more focal lesions.1,2 Risk factors for poor primary
patency after iliac artery angioplasty are associated with
the indication, lesion severity, runoff, patient’s sex, and
the anatomic location of the lesion.3-6 Several observa-
tional studies have shown that endovascular procedures of
external iliac artery (EIA) lesions generally have lower
patency rates than those seen in common iliac artery
(CIA) lesions.1,3,4 The effect of anatomic location on stent
patency is probably related to a smaller diameter and lower
flow in EIAs compared with CIAs.7 Female sex has also
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Objective: The effect of anatomic location of stent placement on the outcome of iliac artery angioplasty and stenting is
not defined. Analyses of patency rates of external iliac artery (EIA) and common iliac artery (CIA) stents have provided
conflicting results and have not considered men and women independently. The purpose of this study was to estimate
the influence of the anatomic location of stenting on the outcome of iliac angioplasty and stent placement in both men
and women. 
Methods: From 1995 to 1999, 247 iliac angioplasty and stent placement procedures (303 stents) were performed in 67
women and 122 men, and all were included in a retrospective cohort study. The criteria prepared by the Ad Hoc
Committee on Reporting Standards (Society for Vascular Surgery/International Society for Cardiovascular Surgery)
were followed. The TransAtlantic Inter-Society Consensus classification was used to characterize the type of iliac
lesions. Both univariate (Kaplan-Meier [KM]) and multivariate analyses (Cox proportional hazards model) were used
to determine the association among the variables, cumulative patency, limb salvage, and survival. 
Results: Indications for iliac angioplasty with stenting were disabling claudication (65%), limb salvage (33%), and blue
toe syndrome (2%). Primary stenting was performed in 103 procedures (42%). Stents were placed selectively after iliac
angioplasty mainly for residual stenosis or pressure gradient (43%). Patients with EIA stents, as compared with those
who had CIA stents, had more extensive lesions (TransAtlantic Inter-Society Consensus type C lesions), poorer runoff,
smaller vessel size, and less frequency of hyperlipidemia (P < .05). Primary patency rates at 1, 3, and 5 years were 76%,
56%, and 56%, respectively, for patients with EIA stents and 92%, 85%, and 76%, respectively, for those with CIA stents.
Although overall primary patency rates were significantly decreased in patients with EIA lesions (KM, log-rank test, 
P = .001), stratified analyses revealed that women with EIA stents had the poorest outcome, with 61%, 47%, and 23%
primary patency rates at 1, 3, and 5 years, respectively, (KM, log-rank test, P <.001). Cox regression analysis identified
EIA stenting (relative risk, 4.3; 95% CI, 2.3-7.9; P <.001) as an independent predictor of decreased primary patency
in women but not in men. 
Conclusions: Women undergoing EIA angioplasty with stent placement have significantly reduced primary patency rates.
Despite initial technical success, these patients are at increased risk of long-term failure and might require subsequent
procedures to obtain clinical success. Conversely, men undergoing EIA stenting have a more favorable outcome than
women. (J Vasc Surg 2001;34:440-6.)
consistently that the presence of EIA disease is a significant
predictor of poor outcome.13,14 In such studies, however,
men and women have not been considered separately.
The TransAtlantic Inter-Society Consensus (TASC)
working group, a recent multidisciplinary effort, has pub-
lished recommendations for the management of peripheral
arterial disease.15 A new morphologic stratification of iliac
lesions was introduced as an improvement over the out-
dated classifications that have been outmoded by stent use
(not considered at the time of such classifications) and
additional experience with lesion-specific anatomy. Such
consensus statements have not yet been widely used in
publications but clearly reflect the most current standard
of care and evidence-based medicine. 
In this study the outcome of patients undergoing iliac
artery angioplasty and stent placement has been investi-
gated with defined, preoperative, procedural, and artery-
specific factors that are predictive of adverse results. The
most current recommendations and standards were used
to define the different variables.15-17 The effect of
anatomic stenting location (ie, EIA vs CIA) on stent
patency, in particular, was analyzed with men and women
considered independently. 
METHODS
Between July 1995 and December 1999, 247 consec-
utive iliac angioplasty and stent placement procedures
(303 stents in total) were performed in 67 women and
122 men at the University of Tennessee Medical Center at
Knoxville, and all were included in a retrospective cohort
study. All of the patients had evidence of chronic limb
ischemia. Demographic data, risk factors, complications,
and outcome variables were defined according to the cri-
teria prepared and revised by the Ad Hoc Committee on
Reporting Standards (Society for Vascular Surgery/
International Society for Cardiovascular Surgery [SVS/
ISCVS]).16,17 Patients who had undergone a previous iliac
angioplasty, stenting, or both were not included.
Preoperative, intraoperative, and follow-up information
was available in all patients and was obtained through
office and hospital chart review, dictated operative
records, and telephone conversations with patients, physi-
cians, or family members. The study protocol was
approved by the local institutional review board.
The procedures were performed in the angiography
suite by interventional radiologists after consultation with
the attending vascular surgeon, or in the operating room
by vascular surgeons. Arteriography was performed by
means of an ipsilateral or contralateral femoral approach.
A bilateral femoral approach was used frequently for
patients requiring bilateral stent placement. Stents were
placed through 7F or 8F sheaths. A balloon-expandable
Palmaz stent (Cordis J and J, Warren, NJ) was used pref-
erentially for focal lesions, for severely calcified lesions,
and for all lesions adjacent to the aortic bifurcation. A self-
expandable Wallstent (Boston Scientific Vascular, Boston,
Mass) was usually placed for long-segment disease or tor-
tuous iliac arteries, and for contralateral approaches. Stent
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placement was deemed technically successful if there was
less than a 30% residual stenosis and if the gradient across
the treated lesion was less than 5 mm Hg. There was no
strict postoperative surveillance protocol. However, the
patients were usually seen within 2 weeks from the time of
the procedure. Improvement and changes in clinical status
were determined according to each patient’s medical his-
tory and noninvasive vascular laboratory test results. At
the discretion of the attending surgeon, postoperative fol-
low-up (clinical and serial duplex ultrasound scanning
examinations) was conducted every 3 months during the
first postoperative year and every 6 months thereafter.
Arteriography was performed when duplex scanning
revealed a decrease in the ankle/brachial index of 0.15 or
more, or if peak systolic velocities were greater than 300
cm/s. Indications for reintervention included a stenosis 
>60% and a gradient across the lesion greater than 15 mm
Hg with papaverine or greater than 10 mm Hg at rest. All
revisions performed based on these criteria or occlusion
were considered a stent failure and an end of primary
patency.16
The recently developed TASC classification of disease
severity for iliac lesions was used to define the categories
of the lesions.15 Runoff was classified from review of both
preoperative and intraoperative arteriograms (Ad Hoc
Committee on Reporting standards, SVS/ISCVS).16,17
Runoff was assessed in the common femoral artery, super-
ficial femoral artery, and the deep femoral artery. The
angiographic runoff score was further used for subgroup
analysis; scores were categorized as poor runoff (score ≥
than 5) and good runoff (score < 5). Vessel size was deter-
mined according to the maximum balloon size used for
dilatation and measurements of lumen diameter above or
below the lesion that were obtained from arteriography.
A power analysis was performed on the data set to deter-
mine the β error and was based on previous studies.1-6,12-14
Our sample size was large enough to obtain at least 90%
power, with a two-sided type I error rate of 0.05, and to
detect a difference in the 5-year primary patency rates from
75% in patients with CIA stents to 52% in patients with EIA
stents (relative risk [RR], 2).
Demographic data and risk factors were compared
between patients in the EIA and CIA stent groups; uni-
variate analysis of categorical variables was performed with
the Fisher exact test or χ2 with Yates correction, as indi-
cated (χ2 for contingency tables, 2-tailed P value). All
analyses were performed according to the intention-to-
treat principle. Primary angioplasty and stent patency,
limb salvage, and patient survival were determined with
the Kaplan-Meier [KM] method and the log-rank test.18
The Cox proportional hazards model was used for multi-
variate analyses to assess the influence of various risk fac-
tors on stent patency.19,20 Variables that had a P value less
than .25 in the univariate analysis and possible confound-
ing factors were entered into the regression model and
considered significant by forward stepwise selection if 
P was less than .05. For statistical analyses, SPSS for
Windows version 9.0 (SPSS Inc, Chicago, Ill) was used.21
RESULTS
The median age of the 189 patients was 60 years (range,
39-83 years). The median follow-up period was 28 months
(range, 4-66 months). The most commonly associated risk
factors in the overall group were a significant history of
tobacco use (84%), hypertension (74%), hyperlipidemia
(61%), coronary artery disease (59%), and diabetes mellitus
(35%). Indications for revascularization were disabling clau-
dication in 162 procedures (65%), limb salvage in 81 (33%;
ischemic rest pain in 48 [19%]; tissue loss in 33 [14%]), and
blue toe syndrome in 4 (2%). The median preoperative
ankle/brachial index at rest was 0.5 (range, 0-0.9). 
Most procedures were performed percutaneously
(91%) with patients under local anesthesia (79%). A total
of 179 procedures were performed in the angiography
suite and 68 in the operating room. Primary stenting was
performed in 103 patients (42%). Selective stenting was
performed for the following indications: a residual steno-
sis or pressure gradient after angioplasty (43%), a dissec-
tion after balloon angioplasty (7%), a long-segment
occlusion (5%), or an eccentric lesion (3%). Stents were
placed in 46 TASC type A iliac lesions (19%), in 125 type
B lesions (51%), in 63 type C lesions (25%), and in 13
(5%) type D lesions. Palmaz stents were used in 153 pro-
cedures (62%), Wallstents in 84 (34%), and a combination
of both in 10 (4%). Single stents were used in 148 lesions
(60%), two stents in 79 (32%), and three stents in 18 (7%). 
Initial technical success was obtained in 239 proce-
dures (97%). Initial hemodynamic success and clinical
improvement, as defined by the SVS/ISCVS reporting
standards, were obtained in 93% of patients. Forty-two
percent of patients had improved to category +3, 32% to
category +2, and 19% to category +1. Three percent of
patients were unchanged, whereas 4% of patients were
worse (category –1, 2%; category –2, 1%; category –3,
1%). Fifty-five additional concomitant surgical procedures
were performed: 42 infrainguinal bypass grafts, 9 femoro-
femoral bypass grafts, and 4 superficial femoral artery
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angioplasties. There were 16 vascular complications: 12
arterial dissections and four femoral pseudoaneurysms. Six
dissections required surgical intervention and as one
pseudoaneurysm; all of theses patients underwent aorto-
bifemoral bypass grafting and were considered stent fail-
ures. Neither stent infection nor distal embolization
occurred. Thirty-six patients underwent a surgical recon-
struction (27 aortobifemoral, 5 iliofemoral, and 4 femo-
rofemoral bypass grafts) at a median of 8.0 months after
iliac angioplasty and stenting.
A total of 106 (65%) angioplasty and stenting proce-
dures were performed for CIA lesions and 87 (35%) for
EIA lesions (corresponding to 122 and 67 patients, respec-
tively). Forty-five patients had both CIA and EIA stents
placed. Patients in the CIA stent group had a higher fre-
quency of hyperlipidemia, compared with those in the EIA
stent group (70% vs 45%; P = .002), with no other signifi-
cant differences noted by univariate analysis with regard to
patient risk factors (Table I). Sex distribution was similar
between the groups. There were also several differences in
the frequency and distribution of the characteristics of the
iliac lesions between the EIA and CIA stent groups. The
average vessel size or artery diameter, based on the maxi-
mum balloon size used for dilatation, of the EIA was sig-
nificantly smaller than that of the CIA (6.6 ± 1.6 mm vs
7.8 ± 1.5 mm, respectively, P < .001; Table II). However,
the average size of the EIA between men and women was
not significantly different (6.7 ± 0.7 mm vs 6.5 ± 1.9 mm,
respectively). EIA occlusive disease tended to be more
extensive and multifocal, with more TASC type C EIA
lesions, when compared with CIA lesions. Runoff scores
were higher for EIA lesions. Primary stent placement was
more frequently used for EIA lesions than for CIA lesions
(Table II). There were no differences between the EIA and
CIA groups with respect to the type of stent used, type of
lesion (stenosis vs occlusion), or patency of the ipsilateral
superficial femoral artery. 
The cumulative primary patency rates for all patients at
1, 3, and 5 years were 88%, 74%, and 68%, respectively.
Table I. Clinical characteristics of patient groups: EIA stent group and CIA stent group
EIA stent group (%) CIA stent group (%) 
(n = 67) (n = 122) P value
Mean age (y) 59.1 58.3 NS
Female sex 31 (36) 68 (42) NS
Comorbidities
Diabetes mellitus 27 (40) 40 (33) NS
Hypertension 47 (70) 93 (76) NS
Tobacco abuse 57 (85) 102 (84) NS
Coronary artery disease 40 (60) 72 (59) NS
Hyperlipidemia 30 (45) 85 (70) .002*
Renal insufficiency (creatinine level > 1.6 mg/dL) 4 (6) 15 (12) NS
Indications
Claudication 36 (52) 80 (66) NS
Rest pain 17 (25) 25 (21) NS
Tissue loss 15 (22) 16 (13) NS
*χ2 Analysis.
Primary patency rates for patients with EIA stents at 1, 3,
and 5 years were 76%, 56%, and 56%, respectively. Primary
patency rates for patients with CIA stents at 1, 3, and 5
years were 95%, 82%, and 76%, respectively. Patients with
EIA stents had significantly decreased primary patency
rates with respect to those with CIA stents by univariate
analysis (Fig 1). Stratified analyses revealed that women
who had EIA stents had the poorest outcome; primary
patency rates for these patients at 1, 3 and 5 years were
61%, 47% and 23%, respectively, whereas for women who
had CIA stents, such rates were 88%, 72%, and 72%,
respectively, (Fig 2). Although men who had EIA stents
also had decreased primary patency rates compared with
those who had CIA stents, such rates were significantly
higher than those for women with EIA stents (KM, log-
rank test, P = .002; Fig 3).
Primary patency rates were also significantly different
for other variables analyzed. Overall, primary stent
patency was significantly reduced in women, compared
with men (KM, log-rank test, P = .002). Primary patency
rates at 1, 3, and 5 years were 79%, 63%, and 58% for
women and 94%, 80% and 74% for men, respectively. The
primary stent patency for smokers was also significantly
reduced, compared with nonsmokers (KM, log-rank test,
P = .01). Moreover, primary patency rates were signifi-
cantly decreased in lesions with poor runoff (score > 5;
KM, log-rank test, P = .02), TASC type C or D lesions
(KM, log-rank test, P = .05), and lesions in patients under-
going selective stenting (KM, log-rank test, P = .001).
Primary stent patency rates were not significantly different
for other risk factors analyzed. Cox regression analysis
revealed that EIA stenting (RR, 2.2; 95% CI, 1.4-3.7; P =
.002) was an independent predictor of decreased primary
patency for all patients when controlling for the presence
of all other risk factors. Poor runoff (score > 5) and female
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sex were also independent predictors by multivariate
analysis for all patients (Table III). For women, EIA stent-
ing was particularly deleterious, associated with a fourfold
increased risk of stent failure (RR, 4.3; 95% CI, 2.1-8.9; P
< .001). Conversely, EIA stenting was not an independent
predictor of decreased primary stent patency for men.
HRT use was another predictor for reduced primary
patency in women. 
Stratified univariate and multivariate analyses includ-
ing only the less severe lesions (ie, TASC type A and B
lesions, the most amenable for endovascular repair)
Fig 1. Primary stent patency, for all patients, after iliac angio-
plasty and stenting were significantly lower for EIA lesions, com-
pared with CIA lesions (KM, log-rank test, P = .001).
Fig 2. Women undergoing EIA stenting had the lowest primary
stent patency after iliac angioplasty and stenting; primary patency
rates were significantly decreased in women with EIA stents com-
pared with those with CIA stents (KM, log-rank test, P < .001).
Fig 3. Primary stent patency in men after iliac angioplasty, and
stenting was significantly lower for EIA lesions, compared with
CIA lesions (KM, log-rank test, P = .03); however, primary
patency rates were higher for men than for women for all iliac
segments. 
revealed similar results. EIA stenting was an independent
predictor of decreased primary patency in women (RR,
3.2; 95% CI, 1.7-6.3; P = .006) but not in men.
For all patients, limb salvage at 1, 3, and 5 years was
98%, 96%, and 96%, respectively. Limb salvage analyses
with KM and the log-rank test revealed no significant dif-
ferences related to the anatomic location of stenting (EIA
vs CIA). One operative (30-day) death occurred in a
patient after a myocardial infarction sustained 2 days after
the operative procedure. Overall, long-term survival was
95% at 1 year, 87% at 3 years, and 84% at 5 years. 
DISCUSSION
This study indicates that the presence of EIA disease is
a significant predictor of poor outcome in women after
iliac angioplasty and stent placement. The influence of
such anatomic location was not as significant in men. EIA
stenting has generally been found, in previous studies, to
JOURNAL OF VASCULAR SURGERY
444 Timaran et al September 2001
be a risk factor for lower patency rates after iliac artery
angioplasty and stenting.1,3,4 In series with iliac angio-
plasty alone, stratified analyses and evaluation of sub-
groups of patients have also revealed evident differences
about the anatomic location of the lesions.3 Lee et al,12 in
examining anatomic stent patency, found no difference in
patency rates between EIA and CIA stents. Such patency
rates were similar despite the fact that patients with EIA
stents were older and had more ischemic limbs compared
with patients with CIA stents. However, in their study
only male patients were included, and the analyses were
not based on an intention-to-treat principle. Their con-
clusions should not therefore be applied to the female
population.
In recent studies, analysis of the endovascular treat-
ment of multisegment iliac occlusive disease has shown
more consistently that the presence of EIA disease is a sig-
nificant predictor of poor outcome.13,14 Further analyses,
Table II. Distribution, characteristics, and procedural factors of 247 iliac angioplasty and stenting procedures compar-
ing the EIA stent group and the CIA stent group
EIA stent group (%) CIA stent group (%)
(n = 87) (n = 160) P value
Vessel size (mm)* 6.6 ± 1.6 7.8 ± 1.5 < .001†
Iliac disease
Stenosis 83 (95) 154 (96) NS
Occlusion 4 (5) 6 (4) NS
TASC stratification of iliac lesions
Type A 4 (5) 42 (26) .02‡
Type B 42 (52) 93 (58) NS
Type C 32 (37) 18 (12) < .001‡
Type D 6 (6) 7 (4) NS
Primary stent placement 60 (69) 84 (53) .02‡
Poor runoff (score > 5) 20 (23) 19 (11) .03‡
Stent type
Palmaz (balloon-expandable) 46 (53) 107 (67) NS
Wallstent (self-expandable) 36 (41) 48 (30) NS
Both 5 (6) 5 (3) NS
*Based on maximum balloon size used for dilatation.
†Student t test.
‡χ2 Analysis.
Table III. Independent predictors of primary stent patency after iliac angioplasty and stenting*
Coefficient RR† 95% CI‡ P value
All patients
EIA stenting 0.805 2.5 1.5-4.1 .001
Poor runoff (score > 5) 1.145 3.1 1.8-5.5 < .001
Female sex 0.727 2.1 1.3-3.4 .004
Women
EIA stenting 1.457 4.3 2.1-8.8 .001
HRT use 0.745 2.1 1.1-4.2 .03
Men
Poor runoff (score > 5) 1.861 6.4 3.1-13.4 < .001
Selective stenting 1.396 4.1 1.8-9.1 .001
*Variables with a P value < .25 in the univariate analysis and those known to be important and possible confounding factors were entered into the multi-
variate Cox regression models and selected by forward stepwise selection if the P value < .05 (P < .001 for models).
†RR denotes relative risk of of adverse outcome (ie, decreased patency) for each predictor.
‡95% CI denotes 95% confidence interval.
as reported by Powell et al,14 showed that the patients
with extensive EIA disease have poor patency despite rein-
tervention after angioplasty and selective stenting.
External iliac severity was measured by the increase of the
external iliac score, which was derived from the Society of
Cardiovascular and Interventional Radiology classification
system for grading iliac artery lesions.22 Such classifica-
tion, however, has been outmoded by stent use (not con-
sidered at the time these guidelines were introduced) and
additional experiences with lesion-specific anatomy.
Moreover, the authors did not stratify their analyses
according to patients’ sex. Our study has shown that
regardless of lesion severity, EIA occlusive disease is an
independent predictor for decreased primary patency in
women after angioplasty and stenting, but not in men. 
In the current study, female sex was found to con-
tribute to decreased stent patency after iliac angioplasty
and stenting. As recognized by other authors, stratified
analyses and evaluation of subgroups of patients revealed
evident differences between the two sexes.3,5,6,8 In the
subanalysis of external iliac stenosis, for instance,
Johnston3 found a lower patency rate for women than for
men. Smaller vessel size has been suggested as a possible
reason for decreased patency rates in female patients, but
this assumption has also been questioned in the literature
because of inconsistent results.1-7 In our study, vessel size
was not an independent predictor for primary stent failure
and therefore did not account for the adverse results
observed in women who had EIA stents. Moreover, the
average size of the EIA between men and women was not
significantly different, yet the primary stent patency was
reduced for women. Therefore, specific risk factors related
to women are relevant, and iliac angioplasty and stenting
procedures in men and women should be considered inde-
pendently. In our previous study, multivariate analyses
identified HRT use, in addition to the presence of EIA
stenting, as an independent predictor of decreased primary
stent patency in women.9 An increased risk of throm-
boembolic events in patients taking HRT may account for
this adverse outcome. 
Although patients with EIA stenting had a higher fre-
quency of extensive iliac lesions (TASC type C), primary
stent placement, and poorer runoff, these associated risk
factors failed to explain the adverse outcome of women
with EIA stents. Stratified multivariate analyses revealed
that such variables were not independent predictors of
decreased primary patency for women, when controlling
the presence of all risk factors. Conversely, selective stent-
ing (more frequently used for CIA lesions) and poor runoff
were important predictors of primary stent failure in men.
This study does adhere to the current criteria prepared
and revised by the Ad Hoc Committee on Reporting
Standards (SVS/ISCVS).16,17 However, an overestima-
tion of the influence of risk factors particular to those
patients who underwent more than one procedure could
be possible when basing the different analyses on the
number of lesions and procedures. Stratified analyses were
obtained, including both iliac arteries (ie, this time, data
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were not analyzed on a unilateral iliac artery basis). These
additional calculations, considering the patient and not
the stent as the unit of study, revealed similar results: EIA
stenting was an independent predictor of decreased pri-
mary graft patency in women but not in men. 
CONCLUSIONS
Women undergoing external iliac angioplasty and
stent placement have a significantly reduced primary stent
patency. Despite initial technical success, these patients are
at increased risk of long-term failure and might require
subsequent procedures to obtain clinical success. Men
undergoing EIA stenting have a more favorable outcome
than women.
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DISCUSSION
Dr Eugene M. Langan III (Greenville, SC). The group from
the University of Tennessee at Knoxville presents a paper that
examines patient selection for iliac angioplasty and/or stenting.
Their study group includes both common and external iliac artery
percutaneous and open endovascular interventions. Both inter-
ventional radiologists and vascular surgeons performed endovas-
cular procedures in this paper.
Although many parameters are studied, the only barometer
of failure appears to be external iliac artery angioplasty and/or
stenting in women. Of major concern is an overall failure rate,
within an average of less than 7 months, of 43 (17%) of 247 pro-
cedures, or better stated, 43 (23%) of 189 study patients.
In review of this manuscript I congratulate the authors for
placing science above the so-called oculostenotic reflex of treat-
ing every lesion visualized on angiography with a peripheral
intervention. Hopefully, more centers will explore their own
results and report and realize that time-tested vascular surgical
principles do not change completely with the advent of new
technology. Treatment of patients with vascular disease contin-
ues to require conservative philosophy regardless of potential
ease of initial treatment.
This said, I have three questions for the authors. First, the
majority of the iliac artery angioplasty and/or stentings were per-
formed by the interventional radiologists. Were these procedures
performed without true vascular surgical consultation on treat-
ment options, and in some cases would the diseased artery have
been better treated by an open surgical reconstruction to help
reduce a 23% eventual failure rate? More precisely put, were these
patients seen by a “real doctor” prior to treatment?
Second, you state “artery size” when discussing differences
between male and female external iliac arteries; this was actually
balloon size. Did you consider intravascular ultrasound for more
accurate preintervention sizing to avoid overdilatation and injury?
Finally, since all patients in the external iliac artery interven-
tional group, and not just women, had poorer runoff, would you
consider that it actually might have been the distal runoff limita-
tions and not patient gender leading to increased failure?
I would like to thank the association for the honor of the
floor, and Drs Timaran and Stevens et al for a timely advanced
copy of the manuscript.
Dr Carlos Timaran. All the analyses in our study were per-
formed according to the intention to treat principle, and this
means that all patients including those who had initial technical
failures were included in the study. In this regard, our primary
patency rates are similar to those reported in previous studies as
well as those described by the TASC working group.
Second, most of the patients underwent selective stenting,
either for unsuccessful or complicated iliac angioplasty, and in this
setting, there is an increased risk of stent failure. Most of the pro-
cedures were performed by interventional radiologists, at least
initially, and although consultation with vascular surgeons was
frequently obtained, there were some patients with severe lesions
that were probably more amenable to open surgical repair. This
approach has changed, and now more procedures are performed
by vascular surgeons in the operating room.
We do agree that intravascular ultrasound is a good method
to determine vessel size. However, we prefer to use the maximum
balloon size for dilatation because this is the most frequent stan-
dard. This allowed us to compare our data with previously pub-
lished studies.
We did stratify our multivariate analysis and models for
runoff, and we obtained similar results. Primary patency was sig-
nificantly decreased in women with external iliac artery stents.
Dr Kenneth McIntyre (Dallas, Tex). What antiplatelet regimen
was used? Did you use any combination of amino pyridines and
aspirin, as have been used in the coronary stent trials to enhance
patency? Was the antiplatelet regimen the same in both groups?
The second thing is, when the stent failed, was the ischemia
of the leg worsened?
Dr Timaran. Most of the patients received aspirin; however,
there was no standard protocol and not all of the patients received
any kind of antithrombotic therapy.
Not all of the patients who had stent occlusion developed
symptomatic ischemia after the stent failure. However, about 70%
required an additional intervention because of symptoms of
ischemia.
Dr R. James Valentine (Dallas, Tex). Congratulations on a
nice analysis. It has been our clinical impression and experience in
Dallas that young patients under the age of 50 have a worse
patency rate, regardless of whether revascularization is accompa-
nied with angioplasty/stents or open procedures. Have you had a
chance to evaluate the effect of age on your patency rates?
Dr Timaran. Yes. We included age as a factor in the multivari-
ate analysis, and actually we divided our patient population accord-
ing to age. Age was not a significant risk factor, although we saw a
similar phenomenon with lower primary patency rates in younger
patients. However, this is a small group of patients and probably
that is why this difference was not statistically significant. 
